Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells

Cancer Immunology, Immunotherapy

Volumn 54, Issue 4, 2005, Pages 372-382

  De Vleeschouwer, Steven ^a   Arredouani, Mohammed ^a,b   Adé, Martine ^a   Cadot, Pascal ^a   Vermassen, Elke ^a   Ceuppens, Jan L ^a   Van Gool, Stefaan W ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Confocal microscopy; Cytotoxicity; Dendritic cells; Flow cytometry; Malignant glioma; Tumor proteins

Indexed keywords

DENDRITIC CELL VACCINE; FLUORESCEIN ISOTHIOCYANATE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LYSATE; CELL MATURATION; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO CULTURE; MONOCYTE; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINE PRODUCTION;

ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BRAIN NEOPLASMS; DENDRITIC CELLS; FLOW CYTOMETRY; GENES, MHC CLASS I; GENES, MHC CLASS II; GLIOMA; HUMANS; LYMPHOCYTE ACTIVATION; MONOCYTES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 13744252899     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0615-8     Document Type: Article

References (59)

1. Al-Alwan MM, Rowden G, Lee TDG, West KA (2001) Cutting edge: the dendritic cell cytoskeleton is critical for the formation of the immunological synapse. J Immunol 166:1452-1456
2. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89
3. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman L, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458
4. Bertho N, Cerny J, Kim YM, Fiebiger E, Ploegh H, Boes M (2003) Requirements for T cell-polarized tubulation of class II+ compartments in dendritic cells. J Immunol 171:5689-5696
5. Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ (1981) Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 40:201-229
6. Black KL, Chen K, Becker DP, Merrill JE (1992) Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J Neurosurg 77:120-126
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
8. Bullens DM, Rafiq K, Charitidou L, Peng X, Kasran A, Warmerdam PA, Van Gool SW, Ceuppens JL (2001) Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production. Int Immunol 13:181-191
9. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998-1008
10. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A (1997) Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-787
11. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P (1998) Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 77:538-542
12. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-2152
13. Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 88:1-10
14. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JEA, Plets C, Van Gool SW (2004) Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy. J Neurosurg 100:492-499
15. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39:531-536
16. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100:216-232
17. Dredge K, Marriott JB, Todryk SM, Dalgleish AG (2002) Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51:521-531
18. Elliott L, Brooks W, Roszman T (1987) Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 78:919-922
19. Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, Lanzavecchia A, Fransen J, Figdor CG, Piguet V, van Kooyk Y (2002) The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 168:2118-2126
20. Fischer K, Andreesen R, Mackensen A (2002) An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods 259:159-169
21. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E (1982) Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413-2419
22. Gil-Torregrosa BC, Lennon-Dumenil AM, Kessler B, Guermonprez P, Ploegh HL, Fruci D, Endert PV, Amigorena S (2004) Control of cross-presentation during dendritic cell maturation. Eur J Immunol 34:398-407
23. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171:4893-4897
24. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16-25
25. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ (2000) Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 96:1857-1864
26. Huettner C, Czub S, Kerkau S, Roggendorf W, Tonn JC (1997) Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 17:3217-3224
27. Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M, Oizumi K, Itoh K (1999) Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 83:760-764
28. Jefford M, Maraskovsky E, Cebon J, Davis ID (2001) The use of dendritic cells in cancer therapy. Lancet Oncol 2:343-353
29. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337-344
30. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N (1989) Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J Neurosurg 71:211-217
31. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD (1995) Tumor antigens in astrocytic gliomas. Glia 15:244-256
32. Lecoeur H, Fevrier M, Garcia S, Riviere Y, Gougeon ML (2001) A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 253:177-187
33. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Seeker DP, Bronstein JM (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115-1124
34. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, Mischel P, Belldegrun A, Cloughesy TF (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: case report. Neurosurg Focus 9:1-5
35. McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD (2000) Glioma-associated antigen expression in oligodendroglial neoplasms: tenascin and epidermal growth factor receptor. J Histochem Cytochem 48:1103-1110
36. Mellman I, Steinman R (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255-258
37. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL (1997) T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 159:4415-4425
38. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851-2855
39. Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033-1036
40. Ploss A, Lauvau G, Contos B, Kerksiek KM, Guirnalda PD, Leiner I, Lenz LL, Bevan MJ, Pamer EG (2003) Promiscuity of MHC class Ib-restricted T cell responses. J Immunol 171:5948-5955
41. Rawson P, Hermans IF, Huck SP, Roberts JM, Pircher H, Ronchese F (2000) Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells. Cancer Res 60:4493-4498
42. Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112-120
43. Rock KL, Goldberg AL (1999) Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17:739-779
44. Rock KL, Gamble S, Rothstein L (1990) Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918-921
45. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods 196:137-151
46. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118
47. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, Parham GP (2000) In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 183:601-609
48. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5:335-341
49. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P (2003) Survivin is a shared tumorassociated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102:571-576
50. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279-1288
51. Shi Y, Zheng W, Rock KL (2000) Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 97:14590-14595
52. Shortman K, Caux C (1997) Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 15:409-419
53. van der Bruggen P, Bastin J, Gajewski TF, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
54. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD (1992) Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36:41-55
55. Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, Lee PK (2003) Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 171:4927-4933
56. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF (2002) 7-Hydroxystaurosporine-induced apoptosis in 9 L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50:1327-1334 (discussion 34-35)
57. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S (2003) Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg 99:738-745
58. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172-1179
59. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:842-847